Pharmacokinetic interactions between HIV-protease inhibitors in rats

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 5, 1999, Pages 241-247

  Yamaji, Hirokazu ^a   Matsumura, Yasuhiro ^a   Yoshikawa, Yukako ^a   Takada, Kanji ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Drug interaction; Indinavir; Nelfinavir; Pharmacokinetics; Rat liver microsomes; Ritonavir; Saquinavir

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG POTENCY; LIVER MICROSOME; MALE; METABOLIC CLEARANCE RATE; NONHUMAN; RAT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV PROTEASE INHIBITORS; INDINAVIR; MALE; NELFINAVIR; RATS; RATS, WISTAR; RITONAVIR; SAQUINAVIR;

EID: 0033384638     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199907)20:5<241::AID-BDD182>3.0.CO;2-U     Document Type: Article

References (16)

1. Chrusciel RA, Romines KR. Recent developments in HIV protease inhibitor research. Exp Opin Ther Patents 1997; 7: 111-121.
2. Hoetelmans RMW, Reijers MHE, Weverling GJ, Kate RW, Wit FWNM, Mulder JW, Weigel HM, Frissen PHJ, Roos M, Jurriaans S, Schuitemaker H, Wolf F, Beijnen JH, Lange JMA. The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998; 12: F111-F115.
3. Lin JH. Human immunodeficiency virus protease inhibitors from drug design to clinical studies. Adv Drug Deliv Rev 1997; 27: 215-233.
4. Hoetelmans RMW, Meenhorst PL, Mulder JW, Burger DM, Koks CHW, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci 1997; 19: 159-175.
5. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111.
6. Hsu A, Granneman GR, Cao G, Carothers L, El-Shourbagy T, Baroldi P, Erdman K, Brown F, Sun E, Leonard JM. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-464.
7. Hayes KA, Brennan B, Chenery R, Houston JB. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab Dispos 1995; 23: 349-353.
8. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
9. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immnodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4. Drug Metab Dispos 1997; 25: 256-266.
10. Yoshikawa Y, Kato K, Sone H, Takada K. Development and evaluation of noncompartmental pharmacokinetic analysis program 'WinHARMONY' using Visual BASIC language having a function of automatic recognition of terminal elimination phase of plasma drug concentration vs. time profile. Jpn J Clin Pharmacol Ther 1998; 29: 475-487.
11. Kumar GN, Rogrigues AD, Buko AM, Denisson JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-431.
12. Kempf DJ, Marsh KC, Kumar G, Rodrogues AD, Denissen JF, Mcdonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654-660.
13. Cato III A, Cavanaugh J, Shi H, Hsu A, Leonard J, Granneman R. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414-421.
14. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Strozuhuk E, Orza D, Marinina J, Gerber N. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P450 3A4/3A5: mechanism-based inactivation of cytochrome P450 3A by ritonavir. Drug Metab Dispos 1998; 26: 552-561.
15. Molla A, Korneyeva M, Gao Q, Vasavanonda S, Schipper PJ, Mo HM, Markowitz M, Chernyavskiy T, Niu P, Lyons N, Hsu A, Granneman GR, Ho DD, Boucher CAB, Leonard JM, Norbeck DW, Kempf DJ. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996; 2: 760-766.
16. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clin Pharmacokinet 1997; 32: 194-209.